ACT News 213.45 05/30/2014 04:22:22 Actavis Inc (ACT)
Post# of 273254
Posted On: 05/30/2014 5:22:13 AM
Actavis Inc (ACT) 213.45 $ACT
Many Weekly Review Stocks Still Nearing Buy Points
at Investor's Business Daily - Thu May 29, 5:50PM CDT
The market this week signaled a confirmed uptrend, which makes this a crucial time to find stocks to buy at proper buy points. Many leading stocks have already broken out past buy points. That's especially true in transportation, energy and food,...
Actavis, Forest CEOs Team Up To Lead New Drug Giant
at Investor's Business Daily - Thu May 29, 3:47PM CDT
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose...
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK
PR Newswire - Thu May 29, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.
Actavis Confirms Generic Onglyza® Patent Challenge
PR Newswire - Tue May 27, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza®, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
Actavis Builds Base As Annual Earnings Keep Growing
at Investor's Business Daily - Fri May 23, 4:11PM CDT
It's been a busy year for Actavis (ACT) as it continues to grow through acquisitions. The former Watson Pharmaceuticals renamed itself Actavis after buying the latter drugmaker in 2012. In October it bought Irish pharmaceutical Warner Chilcott for...
Forest Laboratories, Inc. Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Thu May 22, 7:31AM CDT
Forest Laboratories, Inc. (NYSE: FRX) today announced that, subject to the close of the pending acquisition (the "Acquisition"
of Forest by Actavis plc (NYSE: ACT), Actavis is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.
Actavis Offers to Guarantee Certain Forest Laboratories Senior Notes in connection with Forest Consent Solicitations
PR Newswire - Thu May 22, 7:30AM CDT
Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition" of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities.
Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina
PR Newswire - Thu May 22, 7:30AM CDT
Today, Analysts Review released its analysts' notes regarding InterMune Inc. (NASDAQ: ITMN), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV) and Illumina Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2807-100free.
Actavis to Present at Goldman Sachs 35th Annual Global Healthcare Conference 2014
PR Newswire - Wed May 21, 7:00AM CDT
Actavis plc (NYSE:ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Goldman Sachs 35th Annual Global Healthcare Conference 2014 in Rancho Palos Verdes, California.
Apple Among IBD's 5 'A-List' Big Cap Leaders
at Investor's Business Daily - Tue May 20, 6:03PM CDT
Apple (AAPL) is the coolest phone for A-listers. With earnings growth rebounding amid strong China demand, the tech titan is among five highly rated large-cap stocks that start with the letter A. IBD's Big Cap Leaders Screen of the Day lists large...
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Legal Setback for Eli Lilly in the UK - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 3:10PM CDT
Eli Lilly (LLY) received a legal setback on Alimta in the UK.
FDA Approvals, Stock Price Updates, and Financial Results Release - Analyst Notes on Pfizer, Actavis, Pharmacyclics, Mallinckrodt and Salix Pharmaceuticals
PR Newswire - Fri May 16, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Pharmacyclics, Inc. (NASDAQ: PCYC), Mallinckrodt PLC (NYSE: MNK) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2541-100free.
Actavis signs agreement to extend distribution of JPI's Concerta
M2 - Thu May 15, 10:14AM CDT
Pharmaceutical company Actavis plc (NYSE:ACT) announced on Thursday that it has extended an agreement with Janssen Pharmaceuticals Inc (JPI) to supply the authorised generic version of JPI's Concerta (methylphenidate hydrochloride extended-release tablets).
Actavis Extends Exclusive Agreement to Distribute Authorized Generic Concerta®
PR Newswire - Thu May 15, 7:45AM CDT
Actavis plc (NYSE: ACT) today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. (JPI) to continue supplying the authorized generic version of JPI's Concerta® (methylphenidate hydrochloride extended-release tablets).
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
PR Newswire - Wed May 14, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders, currently CEO and President of Forest, will become CEO and President, and a member of the Board of Directors. Robert Stewart, President, Actavis Global Operations, will become Chief Operating Officer. Mr. Saunders will report to Mr. Bisaro and the Board of Directors, and Mr. Stewart will report to Mr. Saunders.
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.
Actavis Receives Final Approval for Generic Version of Exalgo®
PR Newswire - Tue May 13, 4:00PM CDT
Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo® (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity.
Actavis to Present at Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014
PR Newswire - Tue May 13, 3:45PM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 in New York City.
Many Weekly Review Stocks Still Nearing Buy Points
at Investor's Business Daily - Thu May 29, 5:50PM CDT
The market this week signaled a confirmed uptrend, which makes this a crucial time to find stocks to buy at proper buy points. Many leading stocks have already broken out past buy points. That's especially true in transportation, energy and food,...
Actavis, Forest CEOs Team Up To Lead New Drug Giant
at Investor's Business Daily - Thu May 29, 3:47PM CDT
Brenton Saunders and Paul Bisaro have a lot of experience in making big pharma deals. Since he became CEO of generic drugmaker Watson Pharmaceuticals in 2007, Bisaro has built the company into a giant through its 2012 buyout of Actavis (ACT), whose...
Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK
PR Newswire - Thu May 29, 4:50AM CDT
Today, Analysts Review released its analysts' notes regarding Merck & Co., Inc. (NYSE: MRK), Actavis plc (NYSE: ACT), Celgene Corporation (NASDAQ: CELG), Bristol-Myers Squibb Co. (NYSE: BMY) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3057-100free.
Actavis Confirms Generic Onglyza® Patent Challenge
PR Newswire - Tue May 27, 3:05PM CDT
Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Saxagliptin Hydrochloride Tablets, 2.5 mg and 5 mg. Actavis' ANDA product is a generic version of AstraZeneca and Bristol-Myers Squibb's Onglyza®, which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
2014 Value Investor 500: The Full List
Dan Dzombak, The Motley Fool - Motley Fool - Sat May 24, 8:01AM CDT
The Value Investor 500 is my attempt to highlight the top 500 publicly traded companies in the U.S. To construct a quality-based list of the top 500 companies in the U.S., I focused on what's really important for investors to pay attention to: ...
Actavis Builds Base As Annual Earnings Keep Growing
at Investor's Business Daily - Fri May 23, 4:11PM CDT
It's been a busy year for Actavis (ACT) as it continues to grow through acquisitions. The former Watson Pharmaceuticals renamed itself Actavis after buying the latter drugmaker in 2012. In October it bought Irish pharmaceutical Warner Chilcott for...
Forest Laboratories, Inc. Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Thu May 22, 7:31AM CDT
Forest Laboratories, Inc. (NYSE: FRX) today announced that, subject to the close of the pending acquisition (the "Acquisition"
of Forest by Actavis plc (NYSE: ACT), Actavis is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. Actavis Offers to Guarantee Certain Forest Laboratories Senior Notes in connection with Forest Consent Solicitations
PR Newswire - Thu May 22, 7:30AM CDT
Actavis plc (NYSE: ACT) today announced that, subject to the close of its pending acquisition (the "Acquisition"
of Forest Laboratories, Inc. (NYSE: FRX), it is offering to guarantee certain of Forest's outstanding debt securities in exchange for the elimination of the existing registration rights obligations with respect to those outstanding debt securities. Study Results, Extension of Supply Agreements, Drug Designations, Senior Level Appointments, and Upcoming Events - Analyst Notes on InterMune, Actavis, Bristol-Myers, AbbVie and Illumina
PR Newswire - Thu May 22, 7:30AM CDT
Today, Analysts Review released its analysts' notes regarding InterMune Inc. (NASDAQ: ITMN), Actavis Plc (NYSE: ACT), Bristol-Myers Squibb Co. (NYSE: BMY), AbbVie Inc. (NYSE: ABBV) and Illumina Inc. (NASDAQ: ILMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2807-100free.
Actavis to Present at Goldman Sachs 35th Annual Global Healthcare Conference 2014
PR Newswire - Wed May 21, 7:00AM CDT
Actavis plc (NYSE:ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Goldman Sachs 35th Annual Global Healthcare Conference 2014 in Rancho Palos Verdes, California.
Apple Among IBD's 5 'A-List' Big Cap Leaders
at Investor's Business Daily - Tue May 20, 6:03PM CDT
Apple (AAPL) is the coolest phone for A-listers. With earnings growth rebounding amid strong China demand, the tech titan is among five highly rated large-cap stocks that start with the letter A. IBD's Big Cap Leaders Screen of the Day lists large...
IBD 50's 5 Drug Giants Include Actavis, Gilead
at Investor's Business Daily - Sat May 17, 9:51AM CDT
With the market wending its way through correction, now is the time to search for stocks primed to grow in the market's next leg up. Today's IBD 50 list of highly rated stocks is an excellent starting point. The computer-generated list ranks U.S....
Legal Setback for Eli Lilly in the UK - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 16, 3:10PM CDT
Eli Lilly (LLY) received a legal setback on Alimta in the UK.
FDA Approvals, Stock Price Updates, and Financial Results Release - Analyst Notes on Pfizer, Actavis, Pharmacyclics, Mallinckrodt and Salix Pharmaceuticals
PR Newswire - Fri May 16, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Actavis plc (NYSE: ACT), Pharmacyclics, Inc. (NASDAQ: PCYC), Mallinckrodt PLC (NYSE: MNK) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2541-100free.
Actavis signs agreement to extend distribution of JPI's Concerta
M2 - Thu May 15, 10:14AM CDT
Pharmaceutical company Actavis plc (NYSE:ACT) announced on Thursday that it has extended an agreement with Janssen Pharmaceuticals Inc (JPI) to supply the authorised generic version of JPI's Concerta (methylphenidate hydrochloride extended-release tablets).
Actavis Extends Exclusive Agreement to Distribute Authorized Generic Concerta®
PR Newswire - Thu May 15, 7:45AM CDT
Actavis plc (NYSE: ACT) today announced that it has reached an agreement with Janssen Pharmaceuticals, Inc. (JPI) to continue supplying the authorized generic version of JPI's Concerta® (methylphenidate hydrochloride extended-release tablets).
Actavis Announces Proposed Senior Leadership Team Effective Following Completion of Forest Laboratories Acquisition
PR Newswire - Wed May 14, 7:00AM CDT
Actavis plc (NYSE: ACT) today announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Laboratories, Inc., which is anticipated at mid-year. Following the close, Paul Bisaro, Chairman and Chief Executive Officer of Actavis, will become Executive Chairman. Brent Saunders, currently CEO and President of Forest, will become CEO and President, and a member of the Board of Directors. Robert Stewart, President, Actavis Global Operations, will become Chief Operating Officer. Mr. Saunders will report to Mr. Bisaro and the Board of Directors, and Mr. Stewart will report to Mr. Saunders.
Agreements, Earnings Releases, Senior-Level Retirements and Appointments, and Marketing Authorizations - Analyst Notes on Actavis, Jazz Pharmaceuticals, Bristol-Myers, Biogen Idec and AbbVie
PR Newswire - Wed May 14, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Actavis plc (NYSE: ACT), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Bristol-Myers Squibb Company (NYSE: BMY), Biogen Idec Inc. (NASDAQ: BIIB) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2434-100free.
Actavis Receives Final Approval for Generic Version of Exalgo®
PR Newswire - Tue May 13, 4:00PM CDT
Actavis plc (NYSE: ACT) today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Mallinckrodt Inc.'s Exalgo® (Hydromorphone Hydrochloride Extended-release Tablets 8 mg, 12 mg and 16 mg). Actavis intends to begin shipping its product shortly and believes that, under applicable Hatch Waxman rules, it may be entitled to marketing exclusivity.
Actavis to Present at Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014
PR Newswire - Tue May 13, 3:45PM CDT
Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that Paul Bisaro, Chairman and CEO of Actavis, will provide an overview and update of the Company's business at the Sanford C. Bernstein Thirtieth Annual Strategic Decisions Conference 2014 in New York City.
(0)
(0)Scroll down for more posts ▼